NR4A1 and breast carcinoma: Immunotherapy revolutionizes cancer therapeutics but shows limited efficacy in hormone receptor-positive (HR<sup>+</sup>)/human epidermal growth factor receptor 2-negative (HER2<sup>-</sup>) breast cancer.